Dow 30

Pfizer (PFE) Valuation Sheet

9-Comparable Valuation Sheet

The main competitors for Pfizer are Johnson & Johnson, Merck Inc. and Eli Lilly. Pfizer’s 2012 revenues of $58.99 billion were second only to Johnson & Johnson’s $69.99 billion. Though it has such high revenues the company is valued at a forward price to earnings multiple of 13.59x, which is lowest within its competition. Pfizer did have the highest gross margin compared to others showing that the company’s cost management is improving and has the potential to further improve given its restructuring plans. This will also lead the company to be valuated at a higher multiple and increase its stock price.

comments powered by Disqus

Forgot Password

Enjoy all premium content at BidnessEtc for free now!

Enjoy all premium content at BidnessEtc for free now!

Sign up now and get your free

13 page report on

Internet of Things

Thank You For Subscribing to

Give us a few moments of your valuable time.

Please fill in our survey. Take the survey